KR20230115516A - Composition for Anti-inflammation Using an Extract of Sargassum - Google Patents

Abstract

The present invention provides extracts from the group consisting of Sargassum confusum extract, Sargassum hemiphyllum extract, Sargassum siliquastrum extract, Sargassum miyabei Yendo extract, and Sargassum patens extract. Provided is an anti-inflammatory composition comprising at least one selected capsular extract.

Description

Composition for Anti-inflammation Using an Extract of Sargassum

The present invention relates to an anti-inflammatory composition comprising a capsular capsular extract, and more particularly, to Sargassum confusum extracts, Sargassum hemiphyllum extracts, Sargassum siliquastrum extracts, and Miaves capsular capsicum (Sargassum) miyabei Yendo) extract and Sargassum patens extract.

Inflammation is a local body's defense response that appears in response to pathological conditions caused by physical trauma, infection by harmful chemicals, bacteria, fungi, and viruses, or irritants among metabolites in the body. Inflammation is triggered by various inflammatory mediators produced from damaged tissues and migrating cells. During the inflammatory reaction, blood plasma accumulates at the inflammatory site, dilutes the toxicity secreted by bacteria, increases blood flow, and is accompanied by symptoms such as erythema, pain, edema, and fever. In normal cases, the living body neutralizes or removes disease factors through an inflammatory response and regenerates damaged tissues to restore normal structures and functions, but in other cases, it may progress to a disease state such as chronic inflammation.

With the recent development of molecular biology, many studies have been conducted on the inflammatory response at the molecular level, and various biochemical phenomena are involved in the inflammatory response. It is known to play an important role in the inflammatory response by producing inflammatory cytokines (Ito T., etal, Curr Drug Traget Inflamm Allergy, 2(3);257-265, 2003). Nitric oxide is synthesized from L-arginine by the action of a synthetic factor of nitric oxide, and NOS has several isoforms. b/NOS (brain NOS) present in the brain, neuronal NOS (nNOS) present in the nervous system, and endothelial NOS (eNOS) present in the vascular endothelial system are always expressed at a constant level in the body, and small amounts are produced by them. Nitric oxide (NO) plays an important role in maintaining homeostasis of the human body by performing various physiological reactions related to blood pressure regulation, neurotransmission, learning, and memory. In contrast, iNOS (induced NOS), the expression of which is induced by certain stimuli, produces excessive NO, and nitric oxide (NO) excessively produced by iNOS reacts with superoxide to form peroxynitrite. will form It acts as a strong oxidant and damages cells, which is involved in various pathological processes including inflammation and cancer (Gupta SC et al., Exp Biol Med., 236;658-671, 2011; Riehemann et al, FEBS Lett, 442;89-94, 1999; Stamler et al., Science, 358;1898-1902, 1992).

On the other hand, cyclooxygenase (COX) has hydroperoxidase activity along with the functions of COX and synthesizes intermediates PGG₂ and PGG₂ from arachidonic acid. It produces double acid A2 (thromboxane A2, TxA2), and COX also has two isoforms. COX-1 is constitutively expressed in most tissues to synthesize prostaglandins (PGs) necessary for cell protection, whereas COX-2 is rapidly induced during inflammatory reactions and produces PGE₂, which is important in causing inflammatory reactions. (Weisz A., Biochem. J., 316:209-215, 1996; (Miller M. J. et al., Mediators of inflammation, 4:387-396, 1995: Appleton L. et al., Adv. Pharmacol., 35:27-28, 1996).

PGE2 is best known as a substance that mediates inflammation and contributes to tissue damage by inducing the production of matrix metalloproteinases (MMPs) in inflammatory diseases such as periodontitis. A large amount of PGE2 is produced in macrophages obtained from patients with rheumatoid arthritis, and the PGE2 produced plays an important role in the inflammatory response and tissue destruction mechanism in rheumatoid arthritis.

PGE₂ not only plays a role as a mediator of the well-known inflammatory response, but also promotes the Th2 type immune response and suppresses the Th1 type immune response, and in macrophages TNF-α, IL-1β, IL-8, IL-12, etc. Its role as a modulator of the immune response, which suppresses the production of inflammatory cytokines and promotes the production of anti-inflammatory cytokines such as IL-10, has been revealed in many studies in recent years.

The expression of iNOS and COX-2, which induce excessive production of NO and PGs, which serve as mediators of these inflammatory responses, are regulated by the nuclear transcription factor NF-κB, which is part of the Rel gene family. As a nucleoprotein, in the cytoplasm, it is present in an inactive form in association with I-κB, but when I-κB kinase is activated by a certain factor, I-κB is detached through a phosphorylation process and activated. The activated NF-κB moves to the nucleus and induces the expression of iNOS and COX-2 genes, which induce an inflammatory response (Oh, G. T. et al., Atherosclerosis, 159(1):17-26, 2001).

Non-steroidal anti-inflammatory drugs (NSAIDS), which are currently widely used as anti-inflammatory drugs, are known to cause serious side effects such as gastrointestinal disorders, liver disorders, and renal disorders. Therefore, it is still necessary to develop new drugs having anti-inflammatory activity, side effects, and continuous effects.

On the other hand, seaweed has historically been widely used by mankind for food or industrial purposes since long ago, and is known to contain various active ingredients such as polyphenol components, polysaccharide components, functional peptides, minerals, and alginic acid. However, research on the anti-inflammatory effect of seaweeds to date has been limited to seaweed, blood, and kelp, and thus anti-inflammatory studies on various seaweeds are needed.

Republic of Korea Patent No. 10-1516317

An object of the present invention is to provide an anti-inflammatory composition with fewer side effects while exhibiting an excellent anti-inflammatory effect by inhibiting the expression of substances mediating inflammation.

In order to achieve the above object, the present invention provides an extract of Sargassum confusum, an extract of Sargassum hemiphyllum, an extract of Sargassum siliquastrum, an extract of Sargassum miyabei Yendo, and a double-headed cap (Sargassum). patens) extract, and an anti-inflammatory composition comprising at least one extract selected from the group consisting of extracts.

Also in one embodiment, the present invention provides a food composition comprising the anti-inflammatory composition.

In another embodiment, the present invention provides a cosmetic composition comprising the anti-inflammatory composition.

In another embodiment, the present invention provides a pharmaceutical composition comprising the anti-inflammatory composition.

The anti-inflammatory composition according to the present invention shows an excellent anti-inflammatory effect by using an extract of Sargassum, which is a seaweed.

In addition, using the Sargassum extract of the present invention, it can be provided as a food composition, cosmetic composition, or pharmaceutical composition for use in improving inflammatory diseases or alleviating inflammatory skin irritation.

1 is a cytotoxicity test result of an anti-inflammatory composition according to an embodiment of the present invention.
Figure 2 is a result showing the nitric oxide generation inhibitory effect of the anti-inflammatory composition according to an embodiment of the present invention.
Figure 3a is a result showing the inflammatory cytokine inhibitory effect of the anti-inflammatory composition according to an embodiment of the present invention.
Figure 3b is a result showing the inflammatory cytokine inhibitory effect of the anti-inflammatory composition according to an embodiment of the present invention.
Figure 3c is a result showing the inflammatory cytokine inhibitory effect of the anti-inflammatory composition according to an embodiment of the present invention.

Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily implement the present invention. However, the present invention may be embodied in many different forms and is not limited to the embodiments described herein.

In one embodiment of the present invention, Sargassum confusum extract, Sargassum hemiphyllum extract, Sargassum siliquastrum extract, Sargassum miyabei Yendo extract, and Sargassum patens Provided is an anti-inflammatory composition comprising at least one type of capsular extract selected from the group consisting of extracts.

As used herein, the term 'extract' has a meaning commonly used in the art as a crude extract in the art as described above, but also includes fractions obtained by additional fractionation of the extract in a broad sense. That is, in the present invention, the capsular extract includes not only those obtained using the above-described extraction solvent, but also those obtained by additionally applying a purification process thereto. For example, a fraction obtained by passing the extract through an ultrafiltration membrane having a certain molecular weight cut-off value, separation by various chromatography (made for separation according to size, charge, hydrophobicity or affinity), etc. Fractions obtained through various purification methods performed are also included in the capsular extract of the present invention. The extract used in the present invention may be prepared in a powder state by additional processes such as distillation under reduced pressure and freeze drying or spray drying.

As used herein, 'anti-inflammatory' is meant to include improvement (relief of symptoms) of an inflammatory disease defined below, inhibition or delay of onset of such a disease.

In addition, in the present specification, the term 'inflammatory disease' is an inflammatory response characterized by a local or systemic biological defense response against external physical and chemical stimuli or infection of external infectious agents such as bacteria, fungi, viruses, and various allergens, or autoimmunity. It can be defined as a pathological symptom that causes These inflammatory responses include activation of various inflammatory mediators and enzymes related to immune cells (iNOS, COX-2), secretion of inflammatory mediators (secretion of NO, TNF-α, IL-6, etc.), body fluid infiltration, cell migration, tissue It is accompanied by a series of complex physiological reactions such as destruction, and is externally manifested by symptoms such as erythema, pain, edema, fever, and deterioration or loss of specific body functions. Since the inflammatory disease may be acute, chronic, ulcerative, allergic or necrotic, so long as any disease is included in the definition of inflammatory disease as described above, whether it is acute, chronic, ulcerative, allergic or Regardless of whether it is necrotic or not.

Sargassum is a generic term for algae of the genus Sargassum. Outwardly, the body is clearly divided into roots, stems, and leaves. The stem is triangular or triangular and twisted. Leaves are bent toward the base from the stem, spatula-shaped or elliptical, and midribs are formed up to the center of the leaf. The upper leaf is lanceolate and has sawtooth projections on the edge, and air bubbles are formed all over the body from the stem. It is a representative type of capsicum used for food. It is dark yellowish brown and can be seen all over the coast of Korea. Mojabansok is a difficult-to-sea plant that is perennial and is a representative type of marine forest in the coastal areas of Korea. About 20 species are collected, including locusts, hoesaeng hats, egg-shaped hats, twisted hats, large leaf hats, single leaf hats, and double-headed hats. About 50 species grow in Japan and Southeast Asia. Places with thick caps are suitable for various coastal animals to obtain food or spawn, and play a very important role in preserving the environment and securing fishery resources. In Korea, many types of capsicum are also edible, and are used as raw materials for the seaweed industry, such as alginic acid, or as fertilizers.

Sargassum confusum grows from the lower intertidal zone to the noon zone. The plant body grows to 0.6-2m by giving out 1 or 2-3 short central branches from the semi-shaped root. The central branch is columnar and has small spines. The lower leaves are oval or spatula-shaped, 7cm long, and the midrib is buried. In addition, there are teeth on the edge of the leaf, but sometimes they disappear. The leaves on the upper part have many changes, but are usually long lanceolate, 3-5 cm long, and both ends are thin. Bubbles are usually formed at the base of small branches and are spherical, and young ones are obovate and have cheoldu (微凸頭). Distributed in Korea, Sakhalin, Kuril Islands, and China.

Sargassum hemiphyllum is brown and spreads with a single or two-stranded stem from the fibrous root, and the central branch grows 30-50cm and gives out side branches. The branch is thread-like and the thickness is 1.5~2mm. Leaves are wedge-shaped or obovate at the lower part of the body, and sawtooth or flat at the upper part. Since the leaves on the upper part are not symmetrical, it is called an even leaf cap. It is mainly distributed in Korea (East Coast, Jeju) and Japan.

Sargassum siliquastrum lives on rocks from the low tide to the low tide. It is usually 2-3m in length, but there are some that reach several tens of meters. It changes in a unique shape depending on the season and the place of origin, but generally, the leaves at the base are wide, do not have double sawtooth, and the branches are three-ringed and twisted in a twisted shape. The upper part is full of air bubbles, so it stands upright in the sea. It is mainly distributed in Korea (Bijindo, Yokjido, Eocheongdo, Jeju Island, etc.) and Japan.

Sargassum miyabei Yendo is dark brown, and several cylindrical stems come out from cushion-shaped roots, and the stems grow long and give out short branches. The leaves are leathery, narrow spatula-shaped, and the edges are dull or smooth. Bubbles are drum-shaped, have spine-shaped leaves at the ends, and grow in the lower intertidal zone.

Sargassum patens are epiphytic in the lower intertidal zone, and the stems standing straight from the large seminiferous roots grow taller than 1m in height. The stem is usually flattened, both edges are thin, and it is divided into many central branches, and these branches are branched again into feathers. The leaves of the basal part are bamboo leaf-shaped, elongated, 5-10mm wide, 2-5cm long, with flat stalks, and sometimes divided, several of which are alternate or attached like feathers. The upper leaves are thin linear and the basal part is constricted, and they are usually alternately attached. The bubbles are oval, obovate, have a flat stalk, and have crown leaves. In Korea, it grows in Ulleungdo, Yeosu, Wando, and Jeju.

As described above, the composition of the present invention contains, as an active ingredient, at least one extract selected from the group consisting of capsular capsular capsular extract, capsicum capsicum extract, capsicum capsicum extract, capsicum capsicum extract, extracts of capsicum capsicum, miabe capsicum extracts, and extracts of capsicum capsicum, as an active ingredient, It can be used for anti-inflammatory purposes by suppressing the secretion of caine (TNF-α, IL-6, IL-1β) and the production of nitric oxide (NO).

In general, in the inflammatory response, LPS (lipopolysaccharide) is an intracellular toxin derived from the cell wall of Gram-negative bacteria and binds to toll-like receptor 4 (TLR4) to activate NF-κB, a transcription factor, and NO, an inflammatory cytokine. and PGE2 to secrete various inflammatory regulating substances.

In this process, the capsular extracts suppress the production of NO, inflammatory substances (IL-1β, IL-6, TNF-α) and PGE2 in a concentration-dependent manner, and thus can be used as anti-inflammatory agents.

The PGE2 is one of the inflammatory mediators and is synthesized by the enzymatic action of phospholipase A2. It starts with the production of arachidonic acid from membrane phospholipid.

The arachidonic acid is converted into prostaglandin G2 by enzymatic action and then becomes an unstable metabolite, prostaglandin H2.

These two processes are promoted by cyclooxygenase (COX), and COX has two or more isoenzymes. Among them, COX-1 is constantly expressed to regulate platelet aggregation, gastric mucosa protection, and renal function. Responsible for physiological functions such as COX-2, which is expressed by stimuli such as inflammation.

PGH₂ produced by OX is an unstable intermediate metabolite, and is metabolized into PGE₂, PGD₂, PGI₂, PGF₂, thromboxane A2 (TXA₂), etc. by various prostanoid synthase depending on the cell type or stimulation.

In addition, PGE synthase (PGES), which is involved in the metabolism of PGH₂ into PGE₂, has been known to have three isoforms: cytosolic PGES (cPGES), microsomal PGES-1 (mPGES-1), and mPGES-2. Among them, the expression of mPGES-1 is increased by inflammatory stimuli such as lipopolysaccharid (LPS), inflammatory cytokines such as IL-1β and TNF-α, and nitric oxide (NO), and is functionally close to COX-2. It is closely linked and is involved in the production of PGE2.

Accordingly, the present invention can exhibit excellent anti-inflammatory effects by inhibiting the expression of inflammatory cytokines and nitric oxide (NO) by using the capsular extract as an active ingredient.

In addition, since natural seaweed is used, there is little burden on the human body and no side effects when used for anti-inflammatory purposes.

The capsular extracts may be used as an anti-inflammatory composition alone or in combination as desired, and may be mixed in various weight ratios.

In one example, the anti-inflammatory composition may include all of the two-headed capricorn extract, the pair-leaf capricorn extract, the pretzel capillaries extract, the Miabe capbanchi extract, and the double-headed capinal capillaries extract, and more specifically, the anti-inflammatory composition in total 100 Each capsular extract may be included in an amount of 10 to 50 parts by weight based on parts by weight.

In another example of the present invention, the anti-inflammatory composition may further include an extract of Angelica czernaevia (Fisch. et Meyer) Kitagawa., an extract of Colpomenia sinuosa, and an extract of Scytosiphon lomentaria. there is.

Angelica czernaevia (Fisch. et Meyer) Kitagawa.) is a dicotyledonous perennial plant of the umbel family Ubelaceae and grows mainly near wetlands in highlands. It grows up to 1m in height and grows straight. Leaves are pinnately compound 2-3 times in radix, with long petioles, and the lower part of the petiole becomes a flat sheath and surrounds the main stem. Leaflets are long egg-shaped or lanceolate, with hard sawtooth on the edge, and the leaves become smaller as they go up, split into 3, and the entire petiole becomes a sheath. Flowers are white, blooming in July or August, hanging in the order of double umbrella-shaped flowers, with ridges on the scapes, with dense hairs on the upper part, 10 to 30 peduncles, 2 to 4 cm long, with dense projections on the inside along with the ridges, and the peduncle is It is about 1 cm long. Guns are several, and rifles are thin, small, and numerous. The corolla is small and has 5 petals, which are bent inside. The fruit is spherical and matures in September to October. The root is used for soothing or headache, and the young leaves are edible. In the present invention, it is preferable to include the fine leaf body extract obtained by extracting the leaves of the small leaf body as an active ingredient.

Colpomenia sinuosa is a seaweed that lives on rocks in the lower intertidal zone or attached to seaweed. When young, the stomach is full of water. It is spherical or irregular in shape and has a thickness of 250 to 350 μm. Cortex with 1-2 layers of square or polygonal cells, inner layer with 2-5 layers of more or less round cells. It is widely distributed throughout the world except in extreme regions.

Scytosiphon lomentaria is a seaweed of the family Gorimatidae. It has a body length of 15 to 60 cm, has narrow wrinkles in some places, and is leathery. Lives on rocks near the intertidal zone and is distributed all over the world.

The anti-inflammatory composition according to the present invention exhibits an excellent anti-inflammatory effect even when only the above-mentioned capsular extract is contained, but it is more excellent than when the composite extract is mixed and used as a composite extract of Buchat end extract, Bulregi end extract, and Goryume extract. May have anti-inflammatory effects.

Specifically, the small leaf body extract, bullegi end extract, and goma extract may be included in 5 to 15 parts by weight, respectively, based on 100 parts by weight of the total anti-inflammatory composition.

The extracts may be extracted using an extraction solvent selected from the group consisting of water, alcohol having 1 to 6 carbon atoms, and mixtures thereof.

The pulverized product obtained by pulverizing the extract may be eluted with a polar solvent such as an alcohol having 1 to 6 carbon atoms such as water, ethanol, or methanol, or a mixed solvent having a mixing ratio of 1:0.1 to 1:10 of alcohol and water. At this time, the extraction temperature may be 10 ℃ to 100 ℃, preferably the extract extracted at room temperature.

The extraction solvent may be used in an amount of 2 to 50 times, preferably 2 to 20 times, based on the weight of the sample. For extraction, the sample may be left for leaching in the extraction solvent for 1 to 72 hours, specifically 1 to 24 hours.

It may be a product obtained by concentrating the filtered extract under reduced pressure with a vacuum rotary evaporator, but is not limited thereto, and includes all extracts, dilutions or concentrates of extracts, dried products obtained by drying extracts, and crude or purified products thereof.

A food composition according to another embodiment of the present invention relates to a food composition comprising the anti-inflammatory composition.

The food composition may be prepared in any form, for example, beverages such as tea, juice, carbonated beverages, and ionic beverages, processed oils such as milk and yogurt, foods such as chewing gum, rice cakes, traditional Korean snacks, bread, snacks, and noodles, It can be manufactured into health functional food preparations such as tablets, capsules, pills, granules, liquid, powder, flakes, pastes, syrups, gels, jellies, and bars.

In addition, in terms of legal and functional classification, any product classification can be followed as long as it conforms to the enforcement regulations at the time of manufacturing and distribution. For example, it is a health functional food according to the "Health Functional Food Act" of Korea, or confectionery, legumes, teas, beverages, It may be special purpose food, etc.

The food composition may include food additives in addition to the extracts.

Food additives may generally be understood as substances that are added to, mixed with, or infiltrated into food in manufacturing, processing, or preserving food. Since food is consumed daily and for a long period of time, its safety must be guaranteed. According to the Food Additive Code under the laws of each country governing the manufacture and distribution of food (referred to as the “Food Sanitation Act” in Korea), safety-guaranteed food additives are limitedly regulated in terms of ingredients or functions. In the Korean Food Additives Codex (Ministry of Food and Drug Safety Notice "Standards and Specifications for Food Additives"), food additives are classified into chemical synthetic products, natural additives, and mixed formulations in terms of ingredients, and these food additives are classified as sweeteners and flavors in terms of functions It is divided into additives, preservatives, emulsifiers, acidulants, and thickeners.

Sweeteners are used to impart appropriate sweetness to foods, and both natural and synthetic sweeteners can be used in the composition of the present invention. Preferably, a natural sweetener is used, and examples of the natural sweetener include sugar sweeteners such as corn syrup solids, honey, sucrose, fructose, lactose, and maltose.

Flavors may be used to improve taste or aroma, and both natural and synthetic flavors may be used. Preferably, it is the case of using a natural one. In case of using natural ones, in addition to flavor, the purpose of enhancing nutrition can also be combined. As a natural flavoring agent, it may be obtained from apples, lemons, tangerines, grapes, strawberries, peaches, etc., or obtained from green tea leaves, roundworms, bamboo leaves, cinnamon, chrysanthemum leaves, jasmine, and the like. In addition, those obtained from ginseng (red ginseng), bamboo shoots, aloe vera, ginkgo, etc. can be used. Natural flavors can be liquid concentrates or solid extracts. In some cases, synthetic flavors may be used, and synthetic flavors may include esters, alcohols, aldehydes, terpenes, and the like.

As preservatives, sodium sorbate, sodium sorbate, potassium sorbate, calcium benzoate, sodium benzoate, potassium benzoate, EDTA (ethylenediaminetetraacetic acid), etc. may be used, and as emulsifiers, acacia gum, carboxymethylcellulose, xanthan gum, pectin and the like, and examples of the acidulant include acid salt, malic acid, fumaric acid, adipic acid, phosphoric acid, gluconic acid, tartaric acid, ascorbic acid, acetic acid, phosphoric acid, and the like. Acidulants may be added to the food composition to have an appropriate acidity for the purpose of inhibiting the growth of microorganisms in addition to improving taste.

As the thickening agent, a suspending agent, a sedimentation agent, a gel forming agent, a swelling agent, and the like may be used.

A food composition according to another embodiment of the present invention relates to a cosmetic composition comprising the anti-inflammatory composition.

When the anti-inflammatory composition is understood as a cosmetic composition, its use can be understood as the relief of inflammatory skin irritation, and in addition to the active ingredients of the extracts, stabilizers, solubilizers, and surfactants commonly used in cosmetic compositions are used. , conventional adjuvants and carriers such as vitamins, colors and flavors.

The cosmetic composition may be prepared in any formulation conventionally prepared in the art, and may be used in solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, It can be formulated as emulsion foundation, wax foundation and spray.

A food composition according to another embodiment of the present invention relates to a pharmaceutical composition comprising the anti-inflammatory composition.

The pharmaceutical composition may be prepared as an oral formulation or parenteral formulation according to the route of administration by a conventional method known in the art, including a pharmaceutically acceptable carrier in addition to the active ingredients of the extracts. Here, "pharmaceutically acceptable" means that it does not inhibit the activity of the active ingredient and does not have toxicity more than is adaptable to the subject of application (prescription).

In addition, when the pharmaceutical composition is prepared as an oral dosage form, powders, granules, tablets, pills, dragees, capsules, solutions, gels, syrups, suspensions, wafers, etc. It can be made into a formulation. Examples of suitable pharmaceutically acceptable carriers include sugars such as lactose, glucose, sucrose, dextrose, sorbitol, mannitol, and xylitol, starches such as corn starch, potato starch, and wheat starch, cellulose, methylcellulose, ethylcellulose, Celluloses such as sodium carboxymethylcellulose and hydroxypropylmethylcellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, magnesium stearate, mineral oil, malt, gelatin, talc, polyol, vegetable oil etc. are mentioned. In the case of formulation, if necessary, diluents and/or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants may be included.

When prepared as a parenteral formulation, it may be formulated in the form of an injection, transdermal administration, nasal inhalation, and suppository along with a suitable carrier according to a method known in the art. In the case of formulation as an injection, suitable carriers include sterile water, ethanol, polyols such as glycerol or propylene glycol, or mixtures thereof, preferably Ringer's solution, PBS (phosphate buffered saline) containing triethanolamine or sterilization for injection water, isotonic solutions such as 5% dextrose, and the like can be used. When formulated as a transdermal formulation, it may be formulated in the form of ointments, creams, lotions, gels, external solutions, pastas, liniments, air rolls, and the like. In the case of nasal inhalation, it can be formulated in the form of an aerosol spray using a suitable propellant such as dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, etc., and when formulated into suppositories, the base is Witepsol ( witepsol), tween 61, polyethylene glycols, cacao fat, laurin fat, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, sorbitan fatty acid esters, and the like may be used.

Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily implement the present invention. However, the present invention may be embodied in many different forms and is not limited to the embodiments described herein.

[Example 1: Confirmation of Anti-Inflammatory Effects of Mojaban Extracts]

Preparation of Mojaban Extracts

Strawberry cap (SC), double-leaved cap (SH), twisted cap (SS), Miabe cap (SMY), and double-headed cap (SP) were collected from the coast of Jeju Island, Korea around August 2021, and salt and other impurities were removed. It was lyophilized and pulverized. After extracting this with methanol three times for 3 hours at a ratio of 1:9, the extract was concentrated using a rotary vacuum concentrator and used in the experiment.

1. Experimental Example 1: Evaluation of cytotoxicity

cell culture

Raw 264.7 macrophages distributed from ATCC were cultured in a 37°C, 5% CO ₂ incubator using DMEM medium supplemented with 10% FBS and 1% antibiotics.

Evaluation of cytotoxicity to macrophages

The cultured Raw 264.7 macrophages were divided into 1x10 ⁵ cells per well in a 96 well plate and pre-cultured for 24 hours. After confirming that the cells were sufficiently adhered to the well plate, each concentration of 0.1, 1, 10, 50, and 100 μg/ml of each capsular extract was added using a serum-free medium, followed by incubation at 37°C and 5% CO ₂ for 24 hours. cultured in. Then, 100 μl of MTT reagent was added, incubated in an incubator at 37°C for 4 hours, the solution was removed, 100 μl of DMSO was dispensed, and incubation was performed at 37°C for 30 minutes. Then, the absorbance was measured at 540 nm using ELISA and calculated according to the formula did

The experimental results are shown in FIG. 1 . Figure 1 shows that the capsular extracts of the present invention did not exhibit any particular cytotoxicity at all tested concentrations.

2. Experimental Example 2: NO (Nitric Oxide) secretion measurement

Raw 264.7 macrophages cultured in the same manner as in Experimental Example 1 were divided into 1x10 ⁵ cells per well in a 96 well plate and pre-cultured for 24 hours. After confirming that the cells were sufficiently attached to the well plate, each capsular extract at a concentration of 62.5 μg/ml was treated using a serum-free medium. After 1 hour, LPS (lipopolysaccharide, 1 μg/mL) was treated and incubated for 24 hours at 37° C., 5% CO ₂ incubator. Collect the supernatant, put it in a microplate, add the same amount of griss reagent (1% sulfanilamide + 0.1% naphthylendiamine dihydrochloride, 1:1), react at room temperature for 10 minutes, measure the absorbance at 540 nm using a microplate reader, and The production amount was measured.

The experimental results are shown in FIG. 2 . According to FIG. 2, all 5 types of capsular extracts of the present invention significantly inhibited NO production compared to the untreated sample.

3. Experimental Example 3: Measurement of inflammatory cytokine secretion

Raw 264.7 macrophages cultured in the same manner as in Experimental Example 1 were divided into 1x10 ⁵ cells per well in a 96 well plate and pre-cultured for 24 hours. After confirming that the cells were sufficiently attached to the well plate, each capsular extract at a concentration of 62.5 μg/ml was treated using a serum-free medium. After 1 hour, LPS (lipopolysaccharide, 1 μg/mL) was treated and incubated for 24 hours at 37° C., 5% CO ₂ incubator. The supernatant was collected and placed in a microplate, and the contents of IL-6, TNF-α and IL-1β were measured using an ELISA kit.

The above experimental results are shown in FIG. 3, and according to this, it was confirmed that all 5 capsular extracts of the present invention effectively reduced the LPS-induced secretion of IL-6, TNF-α, and IL-1β in a concentration-dependent manner.

[Example 2: Confirmation of anti-inflammatory effect of complex extract]

In Example 1, the anti-inflammatory activity test results of the present invention were confirmed by the anti-inflammatory activity of the present invention. Accordingly, the anti-inflammatory activity test results for the composite extract containing all of the five types of capsular extracts, and the composite extract further including the fine leaf body (PH) extract, the bullegi end (CS) extract, and the ringworm (SL) extract An anti-inflammatory activity test was also conducted. Specific composition is shown in parts by weight in Table 1 below.

single extract Complex Extract 1 Complex Extract 2 Complex Extract 3 Complex Extract 4 Complex Extract 5 SC 100 20 20 20 15 10 SH - 20 20 20 10 10 SS - 20 20 10 10 10 SMY - 20 15 10 10 5 SP - 20 10 10 10 5 PH - - 5 10 15 20 CS - - 5 10 15 20 SL - - 5 10 15 20

(Unit: parts by weight) For relative evaluation, the anti-inflammatory test result in the case of treatment with a single SC extract was set as index 5, and the degree of anti-inflammatory effect for other composite extracts was described as an index. The results are shown in Table 2 below.

single extract Complex Extract 1 Complex Extract 2 Complex Extract 3 Complex Extract 4 Complex Extract 5 Inhibition of NO production 5 5 7 8 8 4
Inhibition of inflammatory cytokine production 5 6 8 7 7 5

As shown in Table 2 above, as a result of relative comparison with a single extract for inhibition of NO production and inhibition of inflammatory cytokine production to confirm the anti-inflammatory effect, the anti-inflammatory effect is increased in the case of complex extracts 1 to 4 In particular, it was confirmed that the composite extracts 2 to 4 exhibited an excellent anti-inflammatory effect.

Claims (7)

1 selected from the group consisting of Sargassum confusum extract, Sargassum hemiphyllum extract, Sargassum siliquastrum extract, Sargassum miyabei Yendo extract, and Sargassum patens extract An anti-inflammatory composition comprising an extract of at least one species of moss. According to claim 1,
Small leaf body (Angelica czernaevia (Fisch. et Meyer) Kitagawa.) extract, Colpomenia sinuosa extract and ring plum (Scytosiphon lomentaria) extract further comprising,
Anti-inflammatory composition. According to claim 1,
The composition inhibits the expression of inflammatory cytokines (Cytokine), nitric oxide (NO), iNOS and COX-2, which are substances mediating inflammation,
Anti-inflammatory composition. According to claim 1,
The extract is extracted using an extraction solvent selected from the group consisting of water, alcohol having 1 to 6 carbon atoms, and mixtures thereof,
Anti-inflammatory composition. Comprising the composition according to any one of claims 1 to 4
food composition. Comprising the composition according to any one of claims 1 to 4
cosmetic composition. Comprising the composition according to any one of claims 1 to 4
pharmaceutical composition.